One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since it founding in 1981, the company has introduced breakthrough treatments across several areas of medicine that have provided new hope for patients. Today, approximately 10,000 Genzyme employees serve patients in nearly 100 countries.
Genzyme's products are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and immune disease. The company's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. Genzyme is part of the Sanofi Group.

Genzyme in the UK:
Over the past eight years Genzyme has made capital investments in the UK totalling more than £115 million. Genzyme in the UK employs in the region of 500 people in research, development as well as commercial manufacturing and distribution roles. Genzyme UK comprises three different sites; Oxford, Haverhill and Cambridge.